CompletedNCT00782080
Efficacy and Safety of St. John´s Wort/Valerian Extract Versus Placebo in Children and Adolescents With ADHD
Researchers compared Sedariston and placebo, tracking side effects to assess safety in children and adolescents with ADHD.
Medication studyAges 6–17Germany
Understand this study
What did researchers investigate?
Researchers compared Sedariston and placebo, tracking side effects to assess safety in children and adolescents with ADHD.
Who was this study for?
This study was for people with ADHD. Listed age limits: 6 years to 17 years. Other eligibility criteria applied.
- Listed locations
- Alzey, Germany · Bad Neuenahr, Germany and 2 more locationsSee all locations and recruitment
- Activities
- Medication described in the protocol · Placebo comparator
- Compensation
- Payment and expense reimbursement have not been verified.
Study information
Study start dateJuly 2008
- Recruitment status
- Completed
- Enrollment listed in the registry
- 155
- Sponsor
- Prof. Huss
- Sponsor type
- Individual investigator
- Study type
- Drug
- Intervention type
- Medication / drug
- Study phase
- Phase 3Usually a larger study designed to confirm effectiveness and safety in a broader group.
- Locations
- Germany
- Age range
- From 6 Years to 17 Years
- Official registry ID
- NCT00782080
- Official title
Show the full official title
Efficacy and Safety of St. John´s Wort/Valerian Extract (Sedariston Concentrate) Versus Placebo in Children and Adolescents With Attention Deficit/Hyperactivity Disorder (ADHD)
Recruitment & locations
CompletedAlzey · Bad Neuenahr · Berlin
1 more locations
- Mainz
Questions about this study
What did researchers investigate?
Researchers compared Sedariston and placebo, tracking side effects to assess safety in children and adolescents with ADHD.
Who is behind this study?
The study sponsor is Prof. Huss.
Did this study involve medication?
Yes. The study involved medication, including Sedariston and Placebo.
Who was this study for?
This study was for people with ADHD. Listed age limits: 6 years to 17 years. Other eligibility criteria applied.
Want to find a study that may fit you better?
Answer a few simple questions to explore HopeStage studies by condition, country, and situation.
Find a study that may fit meExplore related studies
Other studies that may be relevant based on condition, country, or study type.
CompletedEUCTR 2010-021533-31
A 40-week, randomized, double-blind, placebo-controlled, multicenter efficacy and safety study of Ritalin® LA in the treatment of adult patients with childhood-onset ADHD
Belgium, Denmark, Germany, + 2 others
CompletedEUCTR 2011-000210-19
A 6-month, open-label extension to a 40-week, randomized, double-blind, placebo-controlled, multicenter efficacy and safety study of Ritalin® LA in the treatment of adult patients with childhood-on...
Belgium, Denmark, Germany, + 1 other
CompletedEUCTR 2005-003002-28
A 7 week multicenter, double-blind, randomized, placebo-controlled cross-over evaluation of the efficacy and safety of a modified-release oral dosage form of methylphenidate-HCl, Ritalin LA® (20 mg...
Germany